Progress in Medicinal Chemistry

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions. Professor Brian Cox is at University of Sussex, Brighton, UK

• Small molecules—Giant leaps for immuno-oncologyLisa Kötzner, Bayard Huck, Sakshi Garg and Klaus UrbahnsP2X7 receptor antagonists for the treatment of systemic inflammatory disordersChristine F. Gelin, Anindya Bhattacharya and Michael A. LetavicDiscovery and development of ASK1 inhibitorsReginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas and David AmantiniAn overview of DNA-encoded libraries—A versatile tool for drug discovery Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen and Nils Jakob Vest Hansen